N@N

Cubist Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference

^{Published on 2009-02-26 10:46:04, Last Modified on 2009-02-26 10:46:50 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that David McGirr, SVP and CFO, will present on Monday, March 16^th, 2009, at 3:55 p.m. ET, at the Cowen and Company 29th Annual Health Care Conference being held at The Boston Marriott Copley Place in Boston, MA. The webcast presentation will include discussion of the company's business activities, financial outlook, and current news.

The live webcast of the presentation will be accessible through Cubist's website at [ www.cubist.com ] in the Investor Relations Conference Calendar section. The webcast will be available on Cubist's website for a period of 30 days after the presentation.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN^® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM I.V.^® (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials — CONSERV™-1 and CONSERV™-2 — for the prevention of blood loss during cardiothoracic surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. The company also has internal pre-IND research programs underway targeting novel antibacterials and Hepatitis C infections. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.